Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer.
Triple Negative Breast Cancer
DRUG: Albumin bound (nab)-paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide|DRUG: paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide
pathologic complete response（pCR）, pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy (ypT0/Tis ypN0), 6 months
Objective Response Rate (ORR), Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR), 3 months|Disease-free survival（DFS）, Disease-free survival refers to the time from surgical resection of breast cancer to clinically confirmed local recurrence, distant metastasis, second primary tumor diagnosis, or patient death., 5 years|Overall survival（OS）, Overall survival is defined as the length of time from random assignment to death or to last contact., 5 years|adverse events（AEs）, AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.03., until 28 days after the last study drug administration
To evaluate the efficacy and safety of P nab-paclitaxel combined with carboplatin versus paclitaxel combined with carboplatin followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer.